Recent Articles By The Author
A 'Mag'nificent Way to Play an AdTech Rebound
Similar to biotech, the small adtech space has been hammered in recent quarters and has likely hit oversold territory.
I'm Skeptical on Markets Until There's Progress on These 2 Fronts
Also, I'd like to see a more dovish stance from the Federal Reserve.
2 Biotech Stocks to Own as M&A Potentially Gathers Steam
I like these names as stand-alone entities but they should also attract interest from larger players.
Let's Pick Through the Carnage in the Biotech Sector for Ways to Play It
An ETF provides one opportunity, as do a few individual stocks.
I'm Giving Dynavax Another Shot -- a Booster Shot
Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
The Great Wake-Up Call
Right now, the only one that believes the Fed can engineer a soft landing is Jerome Powell.
A Long, Potentially Pain-Filled Summer Lies Ahead
The impact of the war in Ukraine on food supplies and the effect of Fed rate hikes on the pace of the economy are big concerns moving forward.
These Stocks Are in the Dumpster, But I'm Diving In
I am selectively doing some bottom fishing in busted IPO territory.
We're Taking Investors to 'Task'
We see a trading opportunity around a fast-growing name whose shares have been hit hard.
Busted IPOs, Yachts and Swimming Naked
The massive pullback in IPOs has exposed a lot of names once the tide receded.